Open Access Full Text Article

RETRACTION

EZH2 Contributes to 5-FU Resistance in Gastric Cancer by Epigenetically Suppressing FBXO32 Expression [Retraction]

Wang C, Li X, Zhang J, Ge Z, Chen H, Hu J. Onco Targets Ther. 2018;11:7853-7864.

We, the Editors and Publisher of OncoTargets and Therapy, have retracted the published article.

Since publication, concerns have been raised about the integrity of the data in the article. This includes the duplication of images in Figures 2, 3, 4 and 5. Specifically,

- The western blot images for Figure 2C, AGS/5-FU and Figure 2D, SGC-7901/5-FU, have been duplicated.
- The flow cytometry images for Figure 2H, SGC-7901/5-FU and Figure 4H, SGC-7901/5-FU, have been duplicated.
- The western blot bands for Figure 3B, AGS/5-FU and SGC-7901/5-FU, have been duplicated.
- The western blot bands for Figure 5A, AGS/5-FU and Figure 5B, SGC-7901/5-FU, have been duplicated.

When approached for an explanation, the authors did not respond to our queries, nor did they provide original data for their study. As verifying the validity of the published work is core to the integrity of the scholarly record, we are therefore retracting the article and the authors were notified of this.

We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as "Retracted".

OncoTargets and Therapy

Dovepress

673

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

https://doi.org/10.2147/OTT.S433399

Received: 1 August 2023 Accepted: 1 August 2023 Published: 2 August 2023

OncoTargets and Therapy 2023:16 673

© 2023 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com. terms.php and incorporate the Creative Commons Attribution — Non Commercial (unported, v3.0). License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).